Tim J Kruser1, Bradley P McCabe, Minesh P Mehta, Deepak Khuntia, Toby C Campbell, Heather M Geye, George M Cannon. 1. Departments of *Human Oncology †Medical Physics, University of Wisconsin Carbone Cancer Center ∥Department of Medicine, Division of Hematology and Oncology, University of Wisconsin Carbone Cancer Center, Madison, WI ‡Department of Radiation Oncology, Northwestern Memorial Hospital, Chicago, IL §Western Radiation Oncology, Mountain View, CA.
Abstract
OBJECTIVES: To our knowledge this is the largest report analyzing outcomes for re-irradiation (reRT) for locoregionally recurrent lung cancer, and the first to assess thoracic reRT outcomes in patients with small cell lung cancer (SCLC). METHODS: Forty-eight patients (11 SCLC, 37 non-small cell lung cancer [NSCLC]) receiving reRT to the thorax were identified; 44 (92%) received reRT by intensity-modulated radiotherapy. Palliative responses, survival outcomes, and prognostic factors were analyzed. RESULTS: NSCLC patients received a median of 30 Gy in a median of 10 fractions, whereas SCLC patients received a median of 37.5 Gy in a median of 15 fractions. Median survival for the entire cohort from reRT was 4.2 months. Median survival for NSCLC patients was 5.1 months, versus 3.1 months for the SCLC patients (P=0.15). In NSCLC patients, multivariate analysis demonstrated that Karnofsky performance status≥80 and higher radiation dose were associated with improved survival following reRT, and 75% of patients with symptoms experienced palliative benefit. In SCLC, 4 patients treated with the intent of life prolongation for radiographic recurrence had a median survival of 11.7 months. However, acute toxicities and new disease symptoms limited the duration of palliative benefit in the 7 symptomatic SCLC patients to 0.5 months. CONCLUSIONS: ReRT to the thorax for locoregionally recurrent NSCLC can provide palliative benefit, and a small subset of patients may experience long-term survival. Select SCLC patients may experience meaningful survival prolongation after reRT, but reRT for patients with symptomatic recurrence and/or extrathoracic disease did not offer meaningful survival or durable symptom benefit.
OBJECTIVES: To our knowledge this is the largest report analyzing outcomes for re-irradiation (reRT) for locoregionally recurrent lung cancer, and the first to assess thoracic reRT outcomes in patients with small cell lung cancer (SCLC). METHODS: Forty-eight patients (11 SCLC, 37 non-small cell lung cancer [NSCLC]) receiving reRT to the thorax were identified; 44 (92%) received reRT by intensity-modulated radiotherapy. Palliative responses, survival outcomes, and prognostic factors were analyzed. RESULTS:NSCLCpatients received a median of 30 Gy in a median of 10 fractions, whereas SCLCpatients received a median of 37.5 Gy in a median of 15 fractions. Median survival for the entire cohort from reRT was 4.2 months. Median survival for NSCLCpatients was 5.1 months, versus 3.1 months for the SCLCpatients (P=0.15). In NSCLCpatients, multivariate analysis demonstrated that Karnofsky performance status≥80 and higher radiation dose were associated with improved survival following reRT, and 75% of patients with symptoms experienced palliative benefit. In SCLC, 4 patients treated with the intent of life prolongation for radiographic recurrence had a median survival of 11.7 months. However, acute toxicities and new disease symptoms limited the duration of palliative benefit in the 7 symptomatic SCLCpatients to 0.5 months. CONCLUSIONS: ReRT to the thorax for locoregionally recurrent NSCLC can provide palliative benefit, and a small subset of patients may experience long-term survival. Select SCLCpatients may experience meaningful survival prolongation after reRT, but reRT for patients with symptomatic recurrence and/or extrathoracic disease did not offer meaningful survival or durable symptom benefit.
Authors: A T Turrisi; K Kim; R Blum; W T Sause; R B Livingston; R Komaki; H Wagner; S Aisner; D H Johnson Journal: N Engl J Med Date: 1999-01-28 Impact factor: 91.245
Authors: Igor M Poltinnikov; Kevin Fallon; Yian Xiao; Jay E Reiff; Walter J Curran; Maria Werner-Wasik Journal: Int J Radiat Oncol Biol Phys Date: 2005-07-01 Impact factor: 7.038
Authors: Su K Metcalfe; Michael T Milano; Kevin Bylund; Therese Smudzin; Philip Rubin; Yuhchyau Chen Journal: J Thorac Oncol Date: 2010-02 Impact factor: 15.609
Authors: J B Adkison; D Khuntia; S M Bentzen; G M Cannon; W A Tome; H Jaradat; W Walker; A M Traynor; T Weigel; M P Mehta Journal: Technol Cancer Res Treat Date: 2008-12
Authors: William R Kennedy; Prashant Gabani; John Nikitas; Clifford G Robinson; Jeffrey D Bradley; Michael C Roach Journal: Radiother Oncol Date: 2019-08-31 Impact factor: 6.280
Authors: Christoph Pöttgen; Jehad Abu Jawad; Eleni Gkika; Lutz Freitag; Wolfgang Lübcke; Stefan Welter; Thomas Gauler; Martin Schuler; Wilfried Ernst Erich Eberhardt; Georgios Stamatis; Martin Stuschke Journal: J Thorac Dis Date: 2015-03 Impact factor: 2.895
Authors: Donatella Caivano; Maurizio Valeriani; Sara De Matteis; Paolo Bonome; Ivana Russo; Vitaliana De Sanctis; Giuseppe Minniti; Mattia Falchetto Osti Journal: Radiat Oncol Date: 2018-05-08 Impact factor: 3.481
Authors: Brane Grambozov; Evelyn Nussdorfer; Julia Kaiser; Sabine Gerum; Gerd Fastner; Markus Stana; Christoph Gaisberger; Romana Wass; Michael Studnicka; Felix Sedlmayer; Franz Zehentmayr Journal: Curr Oncol Date: 2021-05-13 Impact factor: 3.677